Levocomp

Levodopa, the active ingredient in Levocomp, is a dopamine precursor and DOPA decarboxylase inhibitor presented as an oral tablet for oral use. It is employed in the management of Parkinson's disease and related Parkinsonian syndromes, helping to restore deficient central dopamine levels. It is commonly combined with carbidopa to enhance central availability and reduce peripheral side effects.

GNH USA supplies Levocomp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Levocomp, a combination of levodopa and carbidopa, is used to treat disorders within the Parkinsonian disease spectrum. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity, tremor and gait disturbances. - Parkinsonian syndrome: alleviates motor impairment caused by dopamine deficiency in secondary Parkinsonism. - Levodopa‑responsive dystonia: reduces dystonic movements and enhances functional mobility.

Levocomp may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or psychosis - Neuroleptic malignant syndrome (very rare)

When prescribing Levocomp, several precautions should be observed to minimise risks. - Dose titration: start with the lowest effective dose and increase gradually under medical supervision. - Monitor for dyskinesia: watch for involuntary movements as therapy progresses. - Assess cardiovascular status: be cautious in patients with a history of hypotension or arrhythmias. - Review concomitant medications: avoid drugs that may diminish levodopa efficacy or increase adverse effects. - Pregnancy and lactation: safety is unknown; use only if the potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Levocomp can interact with several medicines; awareness of major and moderate interactions helps ensure safe use.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): may precipitate hypertensive crisis. - Antipsychotics (e.g., haloperidol, risperidone): can markedly reduce levodopa efficacy. - High‑dose pyridoxine (vitamin B6): increases peripheral levodopa metabolism, lowering central availability.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect may cause symptomatic hypotension. - SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors. - Iron or calcium supplements: may impair levodopa absorption; separate dosing by at least two hours.